Artificial Intelligence

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

A new clinical benchmark published in a Nature journal reveals a Chinese AI is the safest and most effective, challenging Silicon Valley's dominance.

At CES 2026, BLUETTI moves beyond portable power, unveiling smart home batteries, a sodium-ion first, and a vision for a decentralized energy grid.

At CES 2026, RobotEra's L7 humanoid and 'Hexa-Core' lineup showcase China's growing dominance in the global robotics race. Here's a deep dive.

At CES 2026, LumiMind's BCI tech promises to guide you to sleep and power thought-controlled games, raising major scientific and ethical questions.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Fresh off a CES 2026 Innovation Award win, ULS Robotics' new VIATRIX™ exoskeleton promises to bring industrial-strength assistance to everyday adventurers.

Beyond the hype, X-Humanoid's robots are running marathons and working on production lines, signaling a major shift from lab demos to real-world deployment.

At CES 2026, new optical engines from Appotronics promise to make AR glasses as light as normal eyewear, sparking a race toward an affordable, all-day wearable future.

Amid rising virtualization costs, Arcfra's partnership with Netfos introduces a new, AI-ready cloud alternative for Taiwan's tech-driven enterprises.

Biotech leader Arrowhead Pharmaceuticals prices upsized offerings, signaling strong investor confidence and fueling its next wave of RNAi therapies.

As the fitness market booms, TaiSPO 2026 in Taipei unveils the future with smart tech, holistic wellness zones, and a new startup innovation hub.

Nanyang Polytechnic's new AI Nexus Lab, backed by AWS, pairs students with small businesses to solve real-world problems and close Singapore's AI gap.

South Korean gim specialist Daingt is leveraging proprietary data and a 20-year legacy to innovate its seaweed, aiming to dominate the booming global market.

Webull's new Vega AI offers institutional-grade analysis at no cost, shaking up the competitive brokerage market and raising questions for regulators.

Sana Biotechnology prepares for its pivotal J.P. Morgan update, balancing groundbreaking diabetes data against a ticking financial clock and fierce competition.

Amid revenue headwinds and mixed analyst signals, all eyes are on CFO Casey Heller's upcoming investor presentation for signs of a strategic growth pivot.

For the second year running, SolarWinds wins Sterling's Software Partner of the Year, a testament to a strategic alliance driving IT modernization.

A new AI-powered venture is giving abandoned gene therapies a second chance, challenging traditional pharma models to bring hope to rare disease patients.

A new AI staffing agency claims its tech is 12x faster and 7x more accurate. Is this the future of hiring, or a promise technology can't yet keep?